Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tanneberger, S.
Right arrow Articles by Pannuti, Q. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanneberger, S.
Right arrow Articles by Pannuti, Q. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:839-840, 2004
© 2004 European Society for Medical Oncology

Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer-related anaemia controlled better with erythropoietic agents?

S. Tanneberger*, G. Melilli, E. Strocchi, C. Frenquelli and Q. F. Pannuti

Fondazione ANT Italia, Via Curiel 7, 40134 Bologna, Italy

*E-mail: stephan.tanneberger@antitalia.org

The first 10% of the full text of this article appears below.

Randomised clinical trials of erythropoietin have shown a statistically significant substantial reduction in blood transfusions overall, even though the response rate definitions include an increase in haemoglobin by 2 g, which is only achieved in ~60% of patients. Increases in haemoglobin <2 g are achievable in more patients. The review by Cella et al. [1] strongly recommends ‘the use of erythropoietic agents in anemic cancer patients as a means of raising their haemoglobin levels and consequently improving their quality of life’. Anaemia is defined as a ‘a multi-symptom syndrome with fatigue being the primary symptom’, characterized by ‘a haemoglobin level . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
A. Tefferi
Pharmaceutical Erythropoietin Use in Patients With Cancer: Is It Time to Abandon Ship or Just Drop Anchor?
Mayo Clin. Proc., November 1, 2007; 82(11): 1316 - 1318.
[Full Text] [PDF]